{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["Type 2 diabetes mellitus", "animal model", "drug development", "herbal medicine", "insulin resistance"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "33287318", "DateCompleted": {"Year": "2021", "Month": "04", "Day": "06"}, "DateRevised": {"Year": "2021", "Month": "04", "Day": "06"}, "Article": {"ArticleDate": [{"Year": "2020", "Month": "12", "Day": "03"}], "Language": ["eng"], "ELocationID": ["5713", "10.3390/molecules25235713"], "Journal": {"ISSN": "1420-3049", "JournalIssue": {"Volume": "25", "Issue": "23", "PubDate": {"Year": "2020", "Month": "Dec", "Day": "03"}}, "Title": "Molecules (Basel, Switzerland)", "ISOAbbreviation": "Molecules"}, "ArticleTitle": "Bioactive Agent Discovery from the Natural Compounds for the Treatment of Type 2 Diabetes Rat Model.", "Abstract": {"AbstractText": ["Diabetes mellitus is a well-known chronic metabolic disease that poses a long-term threat to human health and is characterized by a relative or absolute lack of insulin, resulting in hyperglycemia. Type 2 diabetes mellitus (T2DM) typically affects many metabolic pathways, resulting in \u03b2-cell dysfunction, insulin resistance, abnormal blood glucose levels, inflammatory processes, excessive oxidative reactions, and impaired lipid metabolism. It also leads to diabetes-related complications in many organ systems. Antidiabetic drugs have been approved for the treatment of hyperglycemia in T2DM; these are beneficial for glucose metabolism and promote weight loss, but have the risk of side effects, such as nausea or an upset stomach. A wide range of active components, derived from medicinal plants, such as alkaloids, flavonoids, polyphenol, quinones, and terpenoids may act as alternative sources of antidiabetic agents. They are usually attributed to improvements in pancreatic function by increasing insulin secretions or by reducing the intestinal absorption of glucose. Ease of availability, low cost, least undesirable side effects, and powerful pharmacological actions make plant-based preparations the key player of all available treatments. Based on the study of therapeutic reagents in the pathogenesis of humans, we use the appropriate animal models of T2DM to evaluate medicinal plant treatments. Many of the rat models have characteristics similar to those in humans and have the advantages of ease of genetic manipulation, a short breeding span, and access to physiological and invasive testing. In this review, we summarize the pathophysiological status of T2DM rat models and focus on several bioactive compounds from herbal medicine with different functional groups that exhibit therapeutic potential in the T2DM rat models, in turn, may guide future approach in treating diabetes with natural drugs."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Cosmetic Science, Providence University, Taichung 43301, Taiwan."}], "LastName": "Yang", "ForeName": "Shih-Chun", "Initials": "SC"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Nutrition and Health Sciences, Chang Gung University of Science and Technology, Kweishan, Taoyuan 33303, Taiwan."}, {"Identifier": [], "Affiliation": "Research Center for Food and Cosmetic Safety, Chang Gung University of Science and Technology, Kweishan, Taoyuan 33303, Taiwan."}, {"Identifier": [], "Affiliation": "Research Center for Chinese Herbal Medicine, Chang Gung University of Science and Technology, Kweishan, Taoyuan 33303, Taiwan."}], "LastName": "Hsu", "ForeName": "Ching-Yun", "Initials": "CY"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Traditional Chinese Medicine, Chang Gung Memorial Hospital, Keelung 20401, Taiwan."}], "LastName": "Chou", "ForeName": "Wei-Ling", "Initials": "WL"}, {"Identifier": ["0000-0003-2114-7709"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Research Center for Food and Cosmetic Safety, Chang Gung University of Science and Technology, Kweishan, Taoyuan 33303, Taiwan."}, {"Identifier": [], "Affiliation": "Research Center for Chinese Herbal Medicine, Chang Gung University of Science and Technology, Kweishan, Taoyuan 33303, Taiwan."}, {"Identifier": [], "Affiliation": "Pharmaceutics Laboratory, Graduate Institute of Natural Products, Chang Gung University, Kweishan, Taoyuan 33303, Taiwan."}, {"Identifier": [], "Affiliation": "Department of Anesthesiology, Chang Gung Memorial Hospital, Kweishan, Taoyuan 33303, Taiwan."}], "LastName": "Fang", "ForeName": "Jia-You", "Initials": "JY"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Pharmaceutics Laboratory, Graduate Institute of Natural Products, Chang Gung University, Kweishan, Taoyuan 33303, Taiwan."}], "LastName": "Chuang", "ForeName": "Shih-Yi", "Initials": "SY"}], "GrantList": [{"GrantID": "CMRPD1K0051-2", "Agency": "Chang Gung Memorial Hospital", "Country": ""}, {"GrantID": "CMRPD1F0331-3", "Agency": "Chang Gung Memorial Hospital", "Country": ""}], "PublicationTypeList": ["Journal Article", "Review"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Molecules", "NlmUniqueID": "100964009", "ISSNLinking": "1420-3049"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Biological Products"}, {"RegistryNumber": "0", "NameOfSubstance": "Hypoglycemic Agents"}, {"RegistryNumber": "0", "NameOfSubstance": "Phytochemicals"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Animals"}, {"QualifierName": ["pharmacology", "therapeutic use"], "DescriptorName": "Biological Products"}, {"QualifierName": ["drug therapy"], "DescriptorName": "Diabetes Mellitus, Type 2"}, {"QualifierName": [], "DescriptorName": "Disease Models, Animal"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["drug therapy"], "DescriptorName": "Hyperglycemia"}, {"QualifierName": ["pharmacology", "therapeutic use"], "DescriptorName": "Hypoglycemic Agents"}, {"QualifierName": ["pharmacology", "therapeutic use"], "DescriptorName": "Phytochemicals"}, {"QualifierName": ["chemistry"], "DescriptorName": "Plants, Medicinal"}, {"QualifierName": [], "DescriptorName": "Rats"}], "CoiStatement": "The authors report no conflicts of interest in this work."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Bliss M. The discovery of insulin: The inside story. Publ. Am. Inst. Hist. Pharm. 1997;16:93\u201399.", "ArticleIdList": ["11619903"]}, {"Citation": "Minkowski O. Historical development of the theory of pancreatic diabetes by Oscar Minkowski, 1929: Introduction and translation by Rachmiel Levine. Diabetes. 1989;38:1\u20136. doi: 10.2337/diab.38.1.1.", "ArticleIdList": ["10.2337/diab.38.1.1", "2642431"]}, {"Citation": "Banting F.G., Best C.H., Collip J.B., Campbell W.R., Fletcher A.A. Pancreatic Extracts in The Treatment of Diabetes Mellitus. Diabetes. 1956;5:69\u201371. doi: 10.2337/diab.5.1.69.", "ArticleIdList": ["10.2337/diab.5.1.69"]}, {"Citation": "M\u00e4rki F., Albrecht W. Biological activity of synthetic human insulin. Diabetologia. 1977;13:293\u2013295. doi: 10.1007/BF01223268.", "ArticleIdList": ["10.1007/BF01223268", "913921"]}, {"Citation": "Monti L., Poma R., Caumo A., Stefani I., Picardi A., Sandoli E., Zoltobrocki M., Micossi P., Pozza G. Intravenous infusion of diarginylinsulin, an insulin analogue: Effects on glucose turnover and lipid levels in insulin-treated type II diabetic patients. Metabolism. 1992;41:540\u2013544. doi: 10.1016/0026-0495(92)90215-V.", "ArticleIdList": ["10.1016/0026-0495(92)90215-V", "1588835"]}, {"Citation": "DeFronzo R.A. From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus. Diabetes. 2009;58:773\u2013795. doi: 10.2337/db09-9028.", "ArticleIdList": ["10.2337/db09-9028", "PMC2661582", "19336687"]}, {"Citation": "Forbes J.M., Cooper M.E. Mechanisms of Diabetic Complications. Physiol. Rev. 2013;93:137\u2013188. doi: 10.1152/physrev.00045.2011.", "ArticleIdList": ["10.1152/physrev.00045.2011", "23303908"]}, {"Citation": "Chillar\u00f3n J.J., Le-Roux J.A.F., Benaiges D., Pedro-Botet J. Type 1 diabetes, metabolic syndrome and cardiovascular risk. Metabolism. 2014;63:181\u2013187. doi: 10.1016/j.metabol.2013.10.002.", "ArticleIdList": ["10.1016/j.metabol.2013.10.002", "24274980"]}, {"Citation": "McCarthy M.I. Genomics, Type 2 Diabetes, and Obesity. N. Engl. J. Med. 2010;363:2339\u20132350. doi: 10.1056/NEJMra0906948.", "ArticleIdList": ["10.1056/NEJMra0906948", "21142536"]}, {"Citation": "Kim K.-A., Shin Y.-J., Akram M., Kim E.-S., Choi K.-W., Suh H., Lee C.-H., Bae O.-N. High Glucose Condition Induces Autophagy in Endothelial Progenitor Cells Contributing to Angiogenic Impairment. Biol. Pharm. Bull. 2014;37:1248\u20131252. doi: 10.1248/bpb.b14-00172.", "ArticleIdList": ["10.1248/bpb.b14-00172", "24989016"]}, {"Citation": "Patel P., Abate N. Body fat distribution and insulin resistance. Nutrients. 2013;5:2019\u20132027. doi: 10.3390/nu5062019.", "ArticleIdList": ["10.3390/nu5062019", "PMC3725490", "23739143"]}, {"Citation": "Kahn S.E., Cooper M.E., Del Prato S. Pathophysiology and treatment of type 2 diabetes: Perspectives on the past, present, and future. Lancet. 2014;383:1068\u20131083. doi: 10.1016/S0140-6736(13)62154-6.", "ArticleIdList": ["10.1016/S0140-6736(13)62154-6", "PMC4226760", "24315620"]}, {"Citation": "He Q., Gao Z., Yin J., Zhang J., Yun Z., Ye J. Regulation of HIF-1\u03b1 activity in adipose tissue by obesity-associated factors: Adipogenesis, insulin, and hypoxia. Am. J. Physiol. Endocrinol. Metab. 2011;300:E877\u2013E885. doi: 10.1152/ajpendo.00626.2010.", "ArticleIdList": ["10.1152/ajpendo.00626.2010", "PMC3093977", "21343542"]}, {"Citation": "Feng Y.-M., Zhao N., Zhang N., Yu C.-G., Zhang Q., Thijs L., Staessen J.A. Insulin Resistance in Relation to Lipids and Inflammation in Type-2 Diabetic Patients and Non-Diabetic People. PLoS ONE. 2016;11:e0153171. doi: 10.1371/journal.pone.0153171.", "ArticleIdList": ["10.1371/journal.pone.0153171", "PMC4830613", "27073920"]}, {"Citation": "Nieto-Vazquez I., Fern\u00e1ndez-Veledo S., Kr\u00e4mer D.K., Vila-Bedmar R., Garcia-Guerra L., Lorenzo M. Insulin resistance associated to obesity: The link TNF-alpha. Arch. Physiol. Biochem. 2008;114:183\u2013194. doi: 10.1080/13813450802181047.", "ArticleIdList": ["10.1080/13813450802181047", "18629684"]}, {"Citation": "Li Z.Y., Song J., Zheng S.L., Fan M.B., Guan Y.F., Qu Y., Xu J., Wang P., Miao C.Y. Adipocyte Metrnl Antagonizes Insulin Resistance through PPARgamma Signaling. Diabetes. 2015;64:4011\u20134022. doi: 10.2337/db15-0274.", "ArticleIdList": ["10.2337/db15-0274", "26307585"]}, {"Citation": "Sears B., Perry M. The role of fatty acids in insulin resistance. Lipids Health Dis. 2015;14:1\u20139. doi: 10.1186/s12944-015-0123-1.", "ArticleIdList": ["10.1186/s12944-015-0123-1", "PMC4587882", "26415887"]}, {"Citation": "Kashyap S., Belfort R., Gastaldelli A., Pratipanawatr T., Berria R., Pratipanawatr W., Bajaj M., Mandarino L., DeFronzo R., Cusi K. A Sustained Increase in Plasma Free Fatty Acids Impairs Insulin Secretion in Nondiabetic Subjects Genetically Predisposed to Develop Type 2 Diabetes. Diabetes. 2003;52:2461\u20132474. doi: 10.2337/diabetes.52.10.2461.", "ArticleIdList": ["10.2337/diabetes.52.10.2461", "14514628"]}, {"Citation": "Nauck M.A., Vardarli I., Deacon C.F., Holst J.J., Meier J.J. Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: What is up, what is down? Diabetologia. 2011;54:10\u201318. doi: 10.1007/s00125-010-1896-4.", "ArticleIdList": ["10.1007/s00125-010-1896-4", "20871975"]}, {"Citation": "Wilding J. The role of the kidneys in glucose homeostasis in type 2 diabetes: Clinical implications and therapeutic significance through sodium glucose co-transporter 2 inhibitors. Metabolism. 2014;63:1228\u20131237. doi: 10.1016/j.metabol.2014.06.018.", "ArticleIdList": ["10.1016/j.metabol.2014.06.018", "25104103"]}, {"Citation": "Obici S., Zhang B.B., Karkanias G., Rossetti L. Hypothalamic insulin signaling is required for inhibition of glucose production. Nat. Med. 2002;8:1376\u20131382. doi: 10.1038/nm1202-798.", "ArticleIdList": ["10.1038/nm1202-798", "12426561"]}, {"Citation": "Garber A.J. Long-Acting Glucagon-Like Peptide 1 Receptor Agonists: A review of their efficacy and tolerability. Diabetes Care. 2011;34:S279\u2013S284. doi: 10.2337/dc11-s231.", "ArticleIdList": ["10.2337/dc11-s231", "PMC3632193", "21525469"]}, {"Citation": "Aroda V.R., Ratner R. The safety and tolerability of GLP-1 receptor agonists in the treatment of type 2 diabetes: A review. Diabetes Metab. Res. Rev. 2011;27:528\u2013542. doi: 10.1002/dmrr.1202.", "ArticleIdList": ["10.1002/dmrr.1202", "21484979"]}, {"Citation": "Abu-Hamdah R., Rabiee A., Meneilly G.S., Shannon R.P., Andersen D.K., Elahi D. Clinical review: The extrapancreatic effects of glucagon-like peptide-1 and related peptides. J. Clin. Endocrinol. Metab. 2009;94:1843\u20131852. doi: 10.1210/jc.2008-1296.", "ArticleIdList": ["10.1210/jc.2008-1296", "PMC2690432", "19336511"]}, {"Citation": "Drucker D.J., Meier J.J. The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368:1696\u20131705. doi: 10.1016/S0140-6736(06)69705-5.", "ArticleIdList": ["10.1016/S0140-6736(06)69705-5", "17098089"]}, {"Citation": "Mooradian A.D., Chehade J., Thurman J.E. The Role of Thiazolidinediones in the Treatment of Patients with Type 2 Diabetes Mellitus. Treat. Endocrinol. 2002;1:13\u201320. doi: 10.2165/00024677-200201010-00002.", "ArticleIdList": ["10.2165/00024677-200201010-00002", "15765617"]}, {"Citation": "Inzucchi S.E., Bergenstal R.M., Buse J.B., Diamant M., Ferrannini E., Nauck M., Peters A.L., Tsapas A., Wender R., Matthews D.R., et al. Management of hyperglycemia in type 2 diabetes: A patient-centered approach: Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetes Care. 2012;35:1364\u20131379. doi: 10.2337/dc12-0413.", "ArticleIdList": ["10.2337/dc12-0413", "PMC3357214", "22517736"]}, {"Citation": "White J.R., Jr. A Brief History of the Development of Diabetes Medications. Diabetes Spectr. 2014;27:82\u201386. doi: 10.2337/diaspect.27.2.82.", "ArticleIdList": ["10.2337/diaspect.27.2.82", "PMC4522877", "26246763"]}, {"Citation": "Calcutt N.A., Cooper M.E., Kern T.S., Schmidt A.M. Therapies for hyperglycaemia-induced diabetic complications: From animal models to clinical trials. Nat. Rev. Drug Discov. 2009;8:417\u2013430. doi: 10.1038/nrd2476.", "ArticleIdList": ["10.1038/nrd2476", "PMC7097138", "19404313"]}, {"Citation": "Al-Awar A., Kupai K., Veszelka M., Sz\u0171cs G., Attieh Z., Murlasits Z., T\u00f6r\u00f6k S., P\u00f3sa A., Varga C. Experimental Diabetes Mellitus in Different Animal Models. J. Diabetes Res. 2016;2016:9051426. doi: 10.1155/2016/9051426.", "ArticleIdList": ["10.1155/2016/9051426", "PMC4993915", "27595114"]}, {"Citation": "Srinivasan K., RamaRao P. Animal models in type 2 diabetes research: An overview. Indian J. Med. Res. 2007;125:451\u2013472.", "ArticleIdList": ["17496368"]}, {"Citation": "Takeda Y., Shimomura T., Asao H., Wakabayashi I. Relationship between Immunological Abnormalities in Rat Models of Diabetes Mellitus and the Amplification Circuits for Diabetes. J. Diabetes Res. 2017;2017:4275851. doi: 10.1155/2017/4275851.", "ArticleIdList": ["10.1155/2017/4275851", "PMC5337356", "28299342"]}, {"Citation": "Cefalu W.T. Animal Models of Type 2 Diabetes: Clinical Presentation and Pathophysiological Relevance to the Human Condition. ILAR J. 2006;47:186\u2013198. doi: 10.1093/ilar.47.3.186.", "ArticleIdList": ["10.1093/ilar.47.3.186", "16804194"]}, {"Citation": "Zhuo J., Zeng Q., Cai D., Zeng X., Chen Y., Gan H., Huang X., Yao N., Huang D., Zhang C. Evaluation of type 2 diabetic mellitus animal models via interactions between insulin and mitogen-activated protein kinase signaling pathways induced by a high fat and sugar diet and streptozotocin. Mol. Med. Rep. 2018;17:5132\u20135142. doi: 10.3892/mmr.2018.8504.", "ArticleIdList": ["10.3892/mmr.2018.8504", "PMC5865978", "29393432"]}, {"Citation": "Guo X.-X., Wang Y., Wang K., Ji B.-P., Zhou F. Stability of a type 2 diabetes rat model induced by high-fat diet feeding with low-dose streptozotocin injection. J. Zhejiang Univ. Sci. B. 2018;19:559\u2013569. doi: 10.1631/jzus.B1700254.", "ArticleIdList": ["10.1631/jzus.B1700254", "PMC6052359", "29971994"]}, {"Citation": "Phillips M.S., Liu Q., Hammond H.A., Dugan V., Hey P.J., Caskey C.T., Hess J.F. Leptin receptor missense mutation in the fatty Zucker rat. Nat. Genet. 1996;13:18\u201319. doi: 10.1038/ng0596-18.", "ArticleIdList": ["10.1038/ng0596-18", "8673096"]}, {"Citation": "Pick A., Clark J., Kubstrup C., Levisetti M., Pugh W., Bonner-Weir S., Polonsky K.S. Role of apoptosis in failure of beta-cell mass compensation for insulin resistance and beta-cell defects in the male Zucker diabetic fatty rat. Diabetes. 1998;47:358\u2013364. doi: 10.2337/diabetes.47.3.358.", "ArticleIdList": ["10.2337/diabetes.47.3.358", "9519740"]}, {"Citation": "Tanaka S.I., Isoda F., Yamakawa T., Ishihara M., Sekihara H. T Lymphopenia in Genetically Obese Rats. Clin. Immunol. Immunopathol. 1998;86:219\u2013225. doi: 10.1006/clin.1997.4467.", "ArticleIdList": ["10.1006/clin.1997.4467", "9473385"]}, {"Citation": "Ruth M.R., Taylor C.G., Zahradka P., Field C.J. Abnormal Immune Responses in fa/fa Zucker Rats and Effects of Feeding Conjugated Linoleic Acid. Obesity (Silver Spring) 2008;16:1770\u20131779. doi: 10.1038/oby.2008.266.", "ArticleIdList": ["10.1038/oby.2008.266", "18483478"]}, {"Citation": "Kawano K., Hirashima T., Mori S., Saitoh Y., Kurosumi M., Natori T. Spontaneous long-term hyperglycemic rat with diabetic complications. Otsuka Long-Evans Tokushima Fatty (OLETF) strain. Diabetes. 1992;41:1422\u20131428. doi: 10.2337/diab.41.11.1422.", "ArticleIdList": ["10.2337/diab.41.11.1422", "1397718"]}, {"Citation": "Kawano K., Hirashima T., Mori S., Natori T. OLETF (Otsuka Long-Evans Tokushima Fatty) rat: A new NIDDM rat strain. Diabetes Res. Clin. Pract. 1994;24:S317\u2013S320. doi: 10.1016/0168-8227(94)90269-0.", "ArticleIdList": ["10.1016/0168-8227(94)90269-0", "7859627"]}, {"Citation": "Lee M.Y., Shim M.S., Kim B.H., Hong S.W., Choi R., Lee E.Y., Nam S.M., Kim G.W., Shin J.Y., Shin Y.G., et al. Effects of Spironolactone and Losartan on Diabetic Nephropathy in a Type 2 Diabetic Rat Model. Diabetes Metab. J. 2011;35:130\u2013137. doi: 10.4093/dmj.2011.35.2.130.", "ArticleIdList": ["10.4093/dmj.2011.35.2.130", "PMC3122897", "21738895"]}, {"Citation": "Dirkes R.K., Ortinau L.C., Rector R.S., Olver T.D., Hinton P.S. Insulin-Stimulated Bone Blood Flow and Bone Biomechanical Properties Are Compromised in Obese, Type 2 Diabetic OLETF Rats. JBMR Plus. 2017;1:116\u2013126. doi: 10.1002/jbm4.10007.", "ArticleIdList": ["10.1002/jbm4.10007", "PMC6124191", "30283885"]}, {"Citation": "Ortinau L.C., Linden M.A., Rector R.S., Hinton P.S. Exercise improves femoral whole-bone and tissue-level biomechanical properties in hyperphagic OLETF rats. Appl. Physiol. Nutr. Metab. 2017;42:884\u2013892. doi: 10.1139/apnm-2017-0077.", "ArticleIdList": ["10.1139/apnm-2017-0077", "28460190"]}, {"Citation": "Goto Y., Kakizaki M., Masaki N., Goto Y., Goto Y. Production of Spontaneous Diabetic Rats by Repetition of Selective Breeding. Tohoku J. Exp. Med. 1976;119:85\u201390. doi: 10.1620/tjem.119.85.", "ArticleIdList": ["10.1620/tjem.119.85", "951706"]}, {"Citation": "Kawano K., Hirashima T., Mori S., Saitoh Y., Kurosumi M., Natori T. An early insulin intervention accelerates pancreatic beta-cell dysfunction in young Goto-Kakizaki rats, a model of naturally occurring noninsulin-dependent diabetes. Endocrinology. 1997;138:1106\u20131110.", "ArticleIdList": ["9048616"]}, {"Citation": "Suzuki S., Toyota T. GK rat. Nihon Rinsho. 1998;56(Suppl. 3):695\u2013699.", "ArticleIdList": ["9513498"]}, {"Citation": "Agardh C.-D., Agardh E., Hultberg B., Qian Y., \u00d6stenson C.-G. The glutathione levels are reduced in Goto-Kakizaki rat retina, but are not influenced by aminoguanidine treatment. Curr. Eye Res. 1998;17:251\u2013256. doi: 10.1076/ceyr.17.3.251.5217.", "ArticleIdList": ["10.1076/ceyr.17.3.251.5217", "9543633"]}, {"Citation": "Murakawa Y., Zhang W., Pierson C.R., Brismar T., Ostenson C.-G., Efendic S., Sima A.A.F. Impaired glucose tolerance and insulinopenia in the GK-rat causes peripheral neuropathy. Diabetes Metab. Res. Rev. 2002;18:473\u2013483. doi: 10.1002/dmrr.326.", "ArticleIdList": ["10.1002/dmrr.326", "12469361"]}, {"Citation": "Homo-Delarche F., Calderari S., Irminger J.-C., Gangnerau M.-N., Coulaud J., Rickenbach K., Dolz M., Halban P., Portha B., Serradas P. Islet Inflammation and Fibrosis in a Spontaneous Model of Type 2 Diabetes, the GK Rat. Diabetes. 2006;55:1625\u20131633. doi: 10.2337/db05-1526.", "ArticleIdList": ["10.2337/db05-1526", "16731824"]}, {"Citation": "Salehi A., Henningsson R., Mosen H., Ostenson C.G., Efendic S., Lundquist I. Dysfunction of the islet lysosomal system conveys impairment of glucose-induced insulin release in the diabetic GK rat. Endocrinology. 1999;140:3045\u20133053. doi: 10.1210/endo.140.7.6862.", "ArticleIdList": ["10.1210/endo.140.7.6862", "10385396"]}, {"Citation": "Dadke S.S., Li H.C., Kusari A.B., Begum N., Kusari J. Elevated Expression and Activity of Protein-Tyrosine Phosphatase 1B in Skeletal Muscle of Insulin-Resistant Type II Diabetic Goto-Kakizaki Rats. Biochem. Biophys. Res. Commun. 2000;274:583\u2013589. doi: 10.1006/bbrc.2000.3188.", "ArticleIdList": ["10.1006/bbrc.2000.3188", "10924321"]}, {"Citation": "Kobayashi T., Nemoto S., Ishida K., Taguchi K., Matsumoto T., Kamata K. Involvement of CaM kinase II in the impairment of endothelial function and eNOS activity in aortas of Type 2 diabetic rats1. Clin. Sci. 2012;123:375\u2013386. doi: 10.1042/CS20110621.", "ArticleIdList": ["10.1042/CS20110621", "22494112"]}, {"Citation": "Furman B.L. Streptozotocin-Induced Diabetic Models in Mice and Rats. Curr. Protoc. Pharmacol. 2015;70:1\u201320. doi: 10.1002/0471141755.ph0547s70.", "ArticleIdList": ["10.1002/0471141755.ph0547s70", "26331889"]}, {"Citation": "Lenzen S. The mechanisms of alloxan- and streptozotocin-induced diabetes. Diabetologia. 2008;51:216\u2013226. doi: 10.1007/s00125-007-0886-7.", "ArticleIdList": ["10.1007/s00125-007-0886-7", "18087688"]}, {"Citation": "Reed M., Meszaros K., Entes L., Claypool M., Pinkett J., Gadbois T., Reaven G. A new rat model of type 2 diabetes: The fat-fed, streptozotocin-treated rat. Metabolism. 2000;49:1390\u20131394. doi: 10.1053/meta.2000.17721.", "ArticleIdList": ["10.1053/meta.2000.17721", "11092499"]}, {"Citation": "Srinivasan K., Viswanad B., Asrat L., Kaul C., Poduri R. Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: A model for type 2 diabetes and pharmacological screening. Pharmacol. Res. 2005;52:313\u2013320. doi: 10.1016/j.phrs.2005.05.004.", "ArticleIdList": ["10.1016/j.phrs.2005.05.004", "15979893"]}, {"Citation": "Zhang M., Lv X.-Y., Li J., Xu Z.-G., Chen L. The Characterization of High-Fat Diet and Multiple Low-Dose Streptozotocin Induced Type 2 Diabetes Rat Model. Exp. Diabetes Res. 2009;2008:704045. doi: 10.1155/2008/704045.", "ArticleIdList": ["10.1155/2008/704045", "PMC2613511", "19132099"]}, {"Citation": "Guo Z., Zhang R., Li J., Xu G. Effect of telmisartan on the expression of adiponectin receptors and nicotinamide adenine dinucleotide phosphate oxidase in the heart and aorta in type 2 diabetic rats. Cardiovasc. Diabetol. 2012;11:94. doi: 10.1186/1475-2840-11-94.", "ArticleIdList": ["10.1186/1475-2840-11-94", "PMC3471013", "22873349"]}, {"Citation": "Hu C., Zhang G., Sun D., Han H., Hu S. Duodenal-jejunal Bypass Improves Glucose Metabolism and Adipokine Expression Independently of Weight Loss in a Diabetic Rat Model. Obes. Surg. 2013;23:1436\u20131444. doi: 10.1007/s11695-013-0976-1.", "ArticleIdList": ["10.1007/s11695-013-0976-1", "23636998"]}, {"Citation": "Dong Y., Chen Y.-T., Yang Y.-X., Zhou X.-J., Dai S.-J., Tong J.-F., Shou D., Li C. Metabolomics Study of Type 2 Diabetes Mellitus and the AntiDiabetic Effect of Berberine in Zucker Diabetic Fatty Rats Using Uplc-ESI-Hdms. Phytother. Res. 2016;30:823\u2013828. doi: 10.1002/ptr.5587.", "ArticleIdList": ["10.1002/ptr.5587", "26888689"]}, {"Citation": "Wang S., He B., Hang W., Wu N., Xia L., Wang X., Zhang Q., Zhou X., Feng Z., Chen Q., et al. Berberine Alleviates Tau Hyperphosphorylation and Axonopathy-Associated with Diabetic Encephalopathy via Restoring PI3K/Akt/GSK3beta Pathway. J. Alzheimers Dis. 2018;65:1385\u20131400. doi: 10.3233/JAD-180497.", "ArticleIdList": ["10.3233/JAD-180497", "30175975"]}, {"Citation": "Guo C., Zhang C.-F., Li L., Wang Z., Xiao W., Yang Z. Hypoglycemic and hypolipidemic effects of oxymatrine in high-fat diet and streptozotocin-induced diabetic rats. Phytomedicine. 2014;21:807\u2013814. doi: 10.1016/j.phymed.2014.02.007.", "ArticleIdList": ["10.1016/j.phymed.2014.02.007", "24680614"]}, {"Citation": "Goboza M., Aboua Y.G., Chegou N.N., Oguntibeju O.O. Vindoline effectively ameliorated diabetes-induced hepatotoxicity by docking oxidative stress, inflammation and hypertriglyceridemia in type 2 diabetes-induced male Wistar rats. Biomed. Pharmacother. 2019;112 doi: 10.1016/j.biopha.2019.108638.", "ArticleIdList": ["10.1016/j.biopha.2019.108638", "30784928"]}, {"Citation": "Ren B., Qin W., Wu F., Wang S., Pan C., Wang L., Zeng B., Ma S., Liang J. Apigenin and naringenin regulate glucose and lipid metabolism, and ameliorate vascular dysfunction in type 2 diabetic rats. Eur. J. Pharmacol. 2016;773:13\u201323. doi: 10.1016/j.ejphar.2016.01.002.", "ArticleIdList": ["10.1016/j.ejphar.2016.01.002", "26801071"]}, {"Citation": "Liu J., Tang Y., Feng Z., Long J. (\u2013)-Epigallocatechin-3-gallate attenuated myocardial mitochondrial dysfunction and autophagy in diabetic Goto-Kakizaki rats. Free Radic. Res. 2014;48:898\u2013906. doi: 10.3109/10715762.2014.920955.", "ArticleIdList": ["10.3109/10715762.2014.920955", "24797301"]}, {"Citation": "Luo C., Yang H., Tang C., Yao G., Kong L., He H., Zhou Y. Kaempferol alleviates insulin resistance via hepatic IKK/NF-kappaB signal in type 2 diabetic rats. Int. Immunopharmacol. 2015;28:744\u2013750. doi: 10.1016/j.intimp.2015.07.018.", "ArticleIdList": ["10.1016/j.intimp.2015.07.018", "26263168"]}, {"Citation": "Sundaram R., Shanthi P., Sachdanandam P. Effect of tangeretin, a polymethoxylated flavone on glucose metabolism in streptozotocin-induced diabetic rats. Phytomedicine. 2014;21:793\u2013799. doi: 10.1016/j.phymed.2014.01.007.", "ArticleIdList": ["10.1016/j.phymed.2014.01.007", "24629597"]}, {"Citation": "Sarkar P., Bhowmick A., Kalita M.C., Banu S. Effects of Resveratrol and Mangiferin on PPARgamma and FALDH Gene Expressions in Adipose Tissue of Streptozotocin-Nicotinamide-Induced Diabetes in Rats. J. Diet. Suppl. 2019;16:659\u2013675. doi: 10.1080/19390211.2018.1472714.", "ArticleIdList": ["10.1080/19390211.2018.1472714", "29985711"]}, {"Citation": "Li Q., Deng S., Zhou X., Yu X., Chen Z. Protection of Curcumin against Streptozocin-Induced Pancreatic Cell Destruction in T2D Rats. Planta Med. 2020;86:113\u2013120.", "ArticleIdList": ["31801161"]}, {"Citation": "Xu W., Liu J., Ma D., Yuan G., Lu Y., Yang Y. Capsaicin reduces Alzheimer-associated tau changes in the hippocampus of type 2 diabetes rats. PLoS ONE. 2017;12:e0172477. doi: 10.1371/journal.pone.0172477.", "ArticleIdList": ["10.1371/journal.pone.0172477", "PMC5321461", "28225806"]}, {"Citation": "Khanra R., Bhattacharjee N., Dua T.K., Nandy A., Saha A., Kalita J., Manna P., Dewanjee S. Taraxerol, a pentacyclic triterpenoid, from Abroma augusta leaf attenuates diabetic nephropathy in type 2 diabetic rats. Biomed. Pharmacother. 2017;94:726\u2013741. doi: 10.1016/j.biopha.2017.07.112.", "ArticleIdList": ["10.1016/j.biopha.2017.07.112", "28802226"]}, {"Citation": "Tian Z., Ren N., Wang J., Zhang D., Zhou Y. Ginsenoside Ameliorates Cognitive Dysfunction in Type 2 Diabetic Goto-Kakizaki Rats. Med. Sci. Monit. 2018;24:3922\u20133928. doi: 10.12659/MSM.907417.", "ArticleIdList": ["10.12659/MSM.907417", "PMC6027254", "29886506"]}, {"Citation": "Thakur V., Nargis S., Gonzalez M., Pradhan S., Terreros D., Chattopadhyay M. Role of Glycyrrhizin in the Reduction of Inflammation in Diabetic Kidney Disease. Nephron. 2017;137:137\u2013147. doi: 10.1159/000477820.", "ArticleIdList": ["10.1159/000477820", "28641285"]}, {"Citation": "Maiti M., Kumar G.S. Polymorphic Nucleic Acid Binding of Bioactive Isoquinoline Alkaloids and Their Role in Cancer. J. Nucleic Acids. 2009;2010 doi: 10.4061/2010/593408.", "ArticleIdList": ["10.4061/2010/593408", "PMC2915887", "20814427"]}, {"Citation": "Agrawal R., Sethiya N.K., Mishra S.H. Antidiabetic activity of alkaloids of Aerva lanata roots on streptozotocin-nicotinamide induced type-II diabetes in rats. Pharm. Biol. 2013;51:635\u2013642. doi: 10.3109/13880209.2012.761244.", "ArticleIdList": ["10.3109/13880209.2012.761244", "23527955"]}, {"Citation": "Testa R., Bonfigli A.R., Genovese S., De Nigris V., Ceriello A. The Possible Role of Flavonoids in the Prevention of Diabetic Complications. Nutrients. 2016;8:310. doi: 10.3390/nu8050310.", "ArticleIdList": ["10.3390/nu8050310", "PMC4882722", "27213445"]}, {"Citation": "Bahadoran Z., Mirmiran P., Azizi F. Dietary polyphenols as potential nutraceuticals in management of diabetes: A review. J. Diabetes Metab. Disord. 2013;12:43. doi: 10.1186/2251-6581-12-43.", "ArticleIdList": ["10.1186/2251-6581-12-43", "23938049"]}, {"Citation": "Jung U.J., Lee M.K., Jeong K.S., Choi M.S. The hypoglycemic effects of hesperidin and naringin are partly mediated by hepatic glucose-regulating enzymes in C57BL/KsJ-db/db mice. J. Nutr. 2004;134:2499\u20132503. doi: 10.1093/jn/134.10.2499.", "ArticleIdList": ["10.1093/jn/134.10.2499", "15465737"]}, {"Citation": "Mahmoud A.M., Ashour M.B., Abdel-Moneim A., Ahmed O.M. Hesperidin and naringin attenuate hyperglycemia-mediated oxidative stress and proinflammatory cytokine production in high fat fed/streptozotocin-induced type 2 diabetic rats. J. Diabetes Complicat. 2012;26:483\u2013490. doi: 10.1016/j.jdiacomp.2012.06.001.", "ArticleIdList": ["10.1016/j.jdiacomp.2012.06.001", "22809898"]}, {"Citation": "Wang Y.-B., Ge Z.-M., Kang W.-Q., Lian Z.-X., Yao J., Zhou C.-Y. Rutin alleviates diabetic cardiomyopathy in a rat model of type 2 diabetes. Exp. Ther. Med. 2015;9:451\u2013455. doi: 10.3892/etm.2014.2090.", "ArticleIdList": ["10.3892/etm.2014.2090", "PMC4280949", "25574214"]}, {"Citation": "Niture N.T., Ansari A.A., Naik S.R. Anti-hyperglycemic activity of rutin in streptozotocin-induced diabetic rats: An effect mediated through cytokines, antioxidants and lipid biomarkers. Indian J. Exp. Boil. 2014;52:720\u2013727.", "ArticleIdList": ["25059040"]}, {"Citation": "Koch W. Dietary Polyphenols-Important Non-Nutrients in the Prevention of Chronic Noncommunicable Diseases. A Systematic Review. Nutrients. 2019;11:1039. doi: 10.3390/nu11051039.", "ArticleIdList": ["10.3390/nu11051039", "PMC6566812", "31075905"]}, {"Citation": "Kasiotis K.M., Pratsinis H., Kletsas D., Haroutounian S.A. Resveratrol and related stilbenes: Their anti-aging and anti-angiogenic properties. Food Chem. Toxicol. 2013;61:112\u2013120. doi: 10.1016/j.fct.2013.03.038.", "ArticleIdList": ["10.1016/j.fct.2013.03.038", "23567244"]}, {"Citation": "Mirzaei H., Shakeri A., Rashidi B., Jalili A., Banikazemi Z., Yaribeygi H. Phytosomal curcumin: A review of pharmacokinetic, experimental and clinical studies. Biomed. Pharmacother. 2017;85:102\u2013112. doi: 10.1016/j.biopha.2016.11.098.", "ArticleIdList": ["10.1016/j.biopha.2016.11.098", "27930973"]}, {"Citation": "Daugherty D.J., Marquez A., Calcutt N.A., Schubert D. A novel curcumin derivative for the treatment of diabetic neuropathy. Neuropharmacology. 2018;129:26\u201335. doi: 10.1016/j.neuropharm.2017.11.007.", "ArticleIdList": ["10.1016/j.neuropharm.2017.11.007", "PMC5841546", "29122628"]}, {"Citation": "Patel S.S., Udayabanu M. Effect of natural products on diabetes associated neurological disorders. Rev. Neurosci. 2017;28:271\u2013293. doi: 10.1515/revneuro-2016-0038.", "ArticleIdList": ["10.1515/revneuro-2016-0038", "28030360"]}, {"Citation": "Faheem N.M., El-Askary A. Neuroprotective role of curcumin on the hippocampus against the structural and serological alterations of streptozotocin-induced diabetes in Sprague Dawely rats. Iran. J. Basic Med. Sci. 2017;20:690\u2013699.", "ArticleIdList": ["PMC5569451", "28868124"]}, {"Citation": "Wu Y., Wang F., Reece E.A., Yang P. Curcumin ameliorates high glucose-induced neural tube defects by suppressing cellular stress and apoptosis. Am. J. Obstet. Gynecol. 2015;212:802.e1\u2013802.e8. doi: 10.1016/j.ajog.2015.01.017.", "ArticleIdList": ["10.1016/j.ajog.2015.01.017", "PMC4457597", "25595578"]}, {"Citation": "Shehzad A., Ha T., Subhan F., Lee Y.S. New mechanisms and the anti-inflammatory role of curcumin in obesity and obesity-related metabolic diseases. Eur. J. Nutr. 2011;50:151\u2013161. doi: 10.1007/s00394-011-0188-1.", "ArticleIdList": ["10.1007/s00394-011-0188-1", "21442412"]}, {"Citation": "Caterina M.J., Schumacher M.A., Tominaga M., Rosen T.A., Levine J.D., Julius D. The capsaicin receptor: A heat-activated ion channel in the pain pathway. Nat. Cell Biol. 1997;389:816\u2013824. doi: 10.1038/39807.", "ArticleIdList": ["10.1038/39807", "9349813"]}, {"Citation": "Mezey E., Toth Z.E., Cortright D.N., Arzubi M.K., Krause J.E., Elde R., Guo A., Blumberg P.M., Szallasi A. Distribution of mRNA for vanilloid receptor subtype 1 (VR1), and VR1-like immunoreactivity, in the central nervous system of the rat and human. Proc. Natl. Acad. Sci. USA. 2000;97:3655\u20133660. doi: 10.1073/pnas.97.7.3655.", "ArticleIdList": ["10.1073/pnas.97.7.3655", "PMC16295", "10725386"]}, {"Citation": "Derbenev A.V., Zsombok A. Potential therapeutic value of TRPV1 and TRPA1 in diabetes mellitus and obesity. Semin. Immunopathol. 2016;38:397\u2013406. doi: 10.1007/s00281-015-0529-x.", "ArticleIdList": ["10.1007/s00281-015-0529-x", "PMC4808497", "26403087"]}, {"Citation": "Gong H., He Z., Peng A., Zhang X., Cheng B., Sun Y., Zheng L., Huang K. Effects of several quinones on insulin aggregation. Sci. Rep. 2014;4:5648. doi: 10.1038/srep05648.", "ArticleIdList": ["10.1038/srep05648", "PMC4090620", "25008537"]}, {"Citation": "Guo M.-Z., Li X.-S., Shen D.-M., Guan X.-Q., Xu H.-R., Gao J. Effect of Rhein on the development of hepatic fibrosis in rats. Zhonghua Gan Zang Bing Za Zhi. 2003;11:26\u201329.", "ArticleIdList": ["12546737"]}, {"Citation": "Du H., Shao J.-Q., Gu P., Wang J., Liu Z. Effect of early intervention with rhein on islet function in db/db mice. Nan Fang Yi Ke Da Xue Xue Bao. 2011;31:1526\u20131529.", "ArticleIdList": ["21945758"]}, {"Citation": "Heo S.-K., Yun H.-J., Park W.-H., Park S.-D. Rhein Inhibits TNF-\u03b1-Induced Human Aortic Smooth Muscle Cell Proliferation via Mitochondrial-Dependent Apoptosis. J. Vasc. Res. 2009;46:375\u2013386. doi: 10.1159/000189798.", "ArticleIdList": ["10.1159/000189798", "19142017"]}, {"Citation": "Shi P., Huang Z., Chen G. Rhein Induces Apoptosis and Cell Cycle Arrest in Human Hepatocellular Carcinoma BEL-7402 Cells. Am. J. Chin. Med. 2008;36:805\u2013813. doi: 10.1142/S0192415X08006259.", "ArticleIdList": ["10.1142/S0192415X08006259", "18711776"]}, {"Citation": "Bordone L., Motta M.C., Picard F., Robinson A., Jhala U.S., Apfeld J., McDonagh T., Lemieux M., McBurney M., Szilvasi A., et al. Sirt1 regulates insulin secretion by repressing UCP2 in pancreatic beta cells. PLoS Biol. 2006;4:e31. doi: 10.1371/journal.pbio.0040295.", "ArticleIdList": ["10.1371/journal.pbio.0040295", "PMC1318478", "16366736"]}, {"Citation": "Picard F., Kurtev M., Chung N., Topark-Ngarm A., Senawong T., Machado De Oliveira R., Leid M., McBurney M.W., Guarente L. Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-gamma. Nature. 2004;429:771\u2013776. doi: 10.1038/nature02583.", "ArticleIdList": ["10.1038/nature02583", "PMC2820247", "15175761"]}, {"Citation": "Gerhart-Hines Z., Rodgers J.T., Bare O., Lerin C., Kim S.-H., Mostoslavsky R., Alt F.W., Wu Z., Puigserver P. Metabolic control of muscle mitochondrial function and fatty acid oxidation through SIRT1/PGC-1\u03b1. EMBO J. 2007;26:1913\u20131923. doi: 10.1038/sj.emboj.7601633.", "ArticleIdList": ["10.1038/sj.emboj.7601633", "PMC1847661", "17347648"]}, {"Citation": "Lee M.S., Sohn C.B. Anti-diabetic Properties of Chrysophanol and Its Glucoside from Rhubarb Rhizome. Biol. Pharm. Bull. 2008;31:2154\u20132157. doi: 10.1248/bpb.31.2154.", "ArticleIdList": ["10.1248/bpb.31.2154", "18981591"]}, {"Citation": "Kim S.J., Kim M.C., Lee B.J., Park D.H., Hong S.H., Um J.Y. Anti-Inflammatory activity of chrysophanol through the suppression of NF-kappaB/caspase-1 activation in vitro and in vivo. Molecules. 2010;15:6436\u20136451. doi: 10.3390/molecules15096436.", "ArticleIdList": ["10.3390/molecules15096436", "PMC6257778", "20877234"]}, {"Citation": "Prateeksha, Yusuf M.A., Singh B.N., Sudheer S., Kharwar R.N., Siddiqui S., Abdel-Azeem A.M., Fraceto L.F., Dashora K., Gupta V.K. Chrysophanol: A Natural Anthraquinone with Multifaceted Biotherapeutic Potential. Biomolecules. 2019;9:68. doi: 10.3390/biom9020068.", "ArticleIdList": ["10.3390/biom9020068", "PMC6406798", "30781696"]}, {"Citation": "Xue P., Zhao J., Zheng A., Li L., Chen H., Tu W., Zhang N., Yu Z., Wang Q., Gu M. Chrysophanol alleviates myocardial injury in diabetic db/db mice by regulating the SIRT1/HMGB1/NF-kappaB signaling pathway. Exp. Ther. Med. 2019;18:4406\u20134412.", "ArticleIdList": ["PMC6862128", "31772635"]}, {"Citation": "Zhang J., Kang H., Wang L., Zhao X. Chrysophanol ameliorates high-fat diet-induced obesity and inflammation in neonatal rats. Die Pharm. 2018;73:228\u2013233.", "ArticleIdList": ["29609691"]}, {"Citation": "Bhattacharjee N., Barma S., Konwar N., Dewanjee S., Manna P. Mechanistic insight of diabetic nephropathy and its pharmacotherapeutic targets: An update. Eur. J. Pharmacol. 2016;791:8\u201324. doi: 10.1016/j.ejphar.2016.08.022.", "ArticleIdList": ["10.1016/j.ejphar.2016.08.022", "27568833"]}, {"Citation": "Cooper M.E. Interaction of metabolic and haemodynamic factors in mediating experimental diabetic nephropathy. Diabetologia. 2001;44:1957\u20131972. doi: 10.1007/s001250100000.", "ArticleIdList": ["10.1007/s001250100000", "11719827"]}, {"Citation": "Luis-Rodr\u00edguez D., Martinez-Castelao A., Gorriz J.L., De-\u00c1lvaro F., Navarro-Gonz\u00e1lez J.F. Pathophysiological role and therapeutic implications of inflammation in diabetic nephropathy. World J. Diabetes. 2012;3:7\u201318. doi: 10.4239/wjd.v3.i1.7.", "ArticleIdList": ["10.4239/wjd.v3.i1.7", "PMC3258536", "22253941"]}], "ReferenceList": []}], "History": [{"Year": "2020", "Month": "10", "Day": "13"}, {"Year": "2020", "Month": "11", "Day": "27"}, {"Year": "2020", "Month": "11", "Day": "27"}, {"Year": "2020", "Month": "12", "Day": "8", "Hour": "1", "Minute": "7"}, {"Year": "2020", "Month": "12", "Day": "9", "Hour": "6", "Minute": "0"}, {"Year": "2021", "Month": "4", "Day": "7", "Hour": "6", "Minute": "0"}, {"Year": "2020", "Month": "12", "Day": "3"}], "PublicationStatus": "epublish", "ArticleIdList": ["33287318", "PMC7731446", "10.3390/molecules25235713", "molecules25235713"]}}], "PubmedBookArticle": []}